Inhalation

INH1024

Issue link: https://www.e-digitaleditions.com/i/1527415

Contents of this Issue

Navigation

Page 17 of 38

16 OctOber 2024 Inhalation References 1. Frohlich, E., et al., Oral inhalation for delivery of proteins and peptides to the lungs. Eur J Pharm Bio- pharm, 2021. 163: p. 198-211. 2. Ibrahim, M., et al., Protein aggregates in inhaled biologics: Challenges and considerations. J Pharm Sci, 2023. 112(5): p. 1341-1344. 3. Joubert, M.K., et al., Classification and charac- terization of therapeutic antibody aggregates. J Biol Chem, 2011. 286(28): p. 25118-25133. 4. Cromwell, M.E., et al., Protein aggregation and bioprocessing. AAPS J, 2006. 8(3): p. E572-E579. 5. Hertel, S.P., et al., Protein stability in pulmonary drug delivery via nebulization. Adv Drug Deliv Rev, 2015. 93: p. 79-94. 6. Kuo, Y.-M., et al., Characterization of vibrating mesh aerosol generators. Aerosol and Air Quality Research, 2019. 19(8): p. 1678-1687. 7. Vecellio, L., e mesh nebuliser: A recent tech- nical innovation for aerosol delivery. Breathe, 2006. 2(3): p. 252-260. 8. Secher, T., et al., Aggregates associated with insta- bility of antibodies during aerosolization induce adverse immunological effects. Pharmaceutics, 2022. 14(3): p. 671. 9. Moussa, E.M., et al., Immunogenicity of thera- peutic protein aggregates. J Pharm Sci, 2016. 105(2): p. 417-430. 10. Pham, N.B., et al., Protein aggregation and immunogenicity of biotherapeutics. Int J Pharm, 2020. 585: p. 119523. 11. Mayor, A., et al., Inhaled IgG1 antibodies: e buffering system is an important driver of stability during mesh-nebulization. Eur J Pharm Biopharm, 2022. 181: p. 173-182. 12. den Engelsman, J., et al., Strategies for the assess- ment of protein aggregates in pharmaceutical biotech product development. Pharm Res, 2011. 28(4): p. 920-933. 13. Bodier-Montagutelli, E., et al., Protein stability during nebulization: Mind the collection step! Eur J Pharm Biopharm, 2020. 152: p. 23-34. 14. Mayor, A., et al., Inhaled antibodies: Formula- tions require specific development to overcome insta- bility due to nebulization. Drug Deliv Transl Res, 2021. 11(4): p. 1625-1633. 15. Hertel, S., et al., Prediction of protein degrada- tion during vibrating mesh nebulization via a high throughput screening method. Eur J Pharm Bio- pharm, 2014. 87(2): p. 386-394. 16. Marschall, C., et al., Preparation of high con- centration protein powder suspensions by milling of lyophilizates. Eur J Pharm Biopharm, 2021. 166: p. 75-86. antigen [37]. With its uniqueness and capacity, it is anticipated that MP would be a valuable addition to the list of orthogonal methods in aggregate analysis. Summary e potential therapeutic values offered by pulmo- nary delivery of proteins have been gaining recog- nition. Atomization involved in nebulization and some particle engineering techniques adds additional risk of protein aggregation through the creation of substantial air-liquid interfaces. To ensure product efficacy and safety, thorough characterization of pro- tein aggregates throughout their product life cycle remains indispensable. To obtain diverse profiles of protein aggregates, orthogonal methodologies with different operating principles should be employed in combination, as each method has its own strengths and pitfalls. is article covers analytical techniques that have been used in the development of inhaled protein formulations, as well as some emerging tech- niques with promising potential. For details on other assessment techniques for protein aggregates, such as fluorescence microscopy, Coulter counter, laser diffractometry, multi-angle laser light scattering, turbidimetry, asymmetrical flow field flow fraction- ation, electron microscopy, atomic force microscopy, small-angle neutron/X-ray scattering, mass spec- trometry and analytical ultracentrifugation, readers are referred to other articles [12, 38]. Critically, it has been reported that the act of aero- sol collection may influence protein stability and alter aggregation profiles, leading to biased measure- ment [5, 13]. For instance, different aerosol sam- plers, ranging from simple polypropylene centrifuge tubes to the compendial Next Generation Impac- tor (NGI), were investigated for their effects on the stability of the collected proteins after nebulization. Results suggested that protein aggregation profiles could be affected by the collection device and the influence was also protein dependent [13]. Charac- terization methods should be judiciously optimized to minimize the risks of interference during sample collection and analysis. Results of protein aggrega- tion profiles should inform or be interpreted with other assessments such as the qualitative analysis of the aggregates and possible aggregation mechanisms, as well as the bioactivity, immunogenicity and tox- icity of the formulations. Latest guidelines issued by relevant drug regulatory authorities concerning the development of therapeutic proteins should be con- sulted, for instance, the European Medicines Agency "Immunogenicity assessment of biotechnology- derived therapeutic proteins—Scientific guideline": https://www.ema.europa.eu/en/immunogenicity- assessment-biotechnology-derived-therapeutic- proteins-scientific-guideline.

Articles in this issue

Links on this page

view archives of Inhalation - INH1024